Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma
NCT ID: NCT06764537
Last Updated: 2025-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
18 participants
INTERVENTIONAL
2025-01-31
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this research is to evaluate the impact of the tumor environment on the antitumor efficacy of anti-GD2 CAR-T therapeutic cells in an in vitro glioblastoma model. Both tumor environment cells and CAR-T therapeutic cells will be generated from glioblastoma patient cells.
The secondary objectives of this research are to
* Evaluate the impact of tumor environment targeting on the in vitro antitumor efficacy of anti-GD2 CAR-T therapeutic cells.
* Evaluate the quality/quantity of generated cells (CAR-T cells and tumor environment cells) in relation to glioblastoma patients.
* Evaluate the efficiency of the cell isolation technique (CAR-T cells and tumor environment cells)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma
NCT05802693
WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients
NCT06691308
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
NCT06815029
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
NCT04406610
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
NCT03283631
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blood collection (40 mL) of glioblastoma patients
Blood collection
Blood collection (40 mL) in glioblastoma patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood collection
Blood collection (40 mL) in glioblastoma patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* WHO 0 to 2
* Patient with a diagnosis of histologically proven de novo glioblastoma with non-mutated IDH status according to WHO 2021 classification
* Patient naïve to any treatment for this cancer
* Patient weighing ≥ 50 kg
* Patient able and willing to follow all study procedures in accordance with the protocol;
* Person affiliated to a social security scheme or beneficiary of such a scheme
* Person who has received full information on the organization of the clinical research and has signed an informed consent form
Exclusion Criteria
* People with a history of cancer \< 5 years old
* Immunocompromised (with immunodeficiency or current immunosuppressive therapy)
* Chronic inflammatory disease
* Person with current infection
* Anyone taking corticosteroids \>10mg/day on the day of blood sampling for research purposes
* Anyone with a contraindication to blood sampling
* Women of childbearing age without effective contraception
* Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code Pregnant, parturient or breast-feeding women Minor (not emancipated) Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice) Persons of full age who are unable to give their consent
* Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care under articles L. 3212-1 and L. 3213-1
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
REPPEL Loïc
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cell Therapy Unit, Nancy Hospital
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RIPH2: 2024-A02098-39 2022PI15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.